Related Experiment Video

Updated: May 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells

Yu-Lin Lin1, Jau-Yu Liau, Shan-Chi Yu

  • 1Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

Plos One
|December 5, 2012
PubMed

Insights

KRAS mutation predicts oxaliplatin sensitivity in colorectal cancer (CRC) by altering ERCC1 expression. This finding offers a potential biomarker for chemotherapy response in CRC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chemotherapy sensitivity prediction in colorectal cancer (CRC) lacks defined biomarkers.
  • KRAS mutation status is crucial in CRC treatment but its role in chemotherapy sensitivity is not fully understood.

Purpose of the Study:

  • To investigate if KRAS mutation status predicts oxaliplatin sensitivity in colorectal cancer (CRC).
  • To elucidate the underlying molecular mechanism involving ERCC1 expression.

Main Methods:

  • Generated paired CRC cell lines with manipulated KRAS expression (knockdown and overexpression).
  • Assessed drug sensitivity to oxaliplatin, irinotecan, and 5FU using MTT assay and flow cytometry.
  • Analyzed ERCC1 protein and mRNA levels via Western blot and qRT-PCR.

Main Results:

  • KRAS overexpression in wild-type cells downregulated ERCC1, enhancing oxaliplatin sensitivity.
  • KRAS knockdown in mutant cells upregulated ERCC1, increasing oxaliplatin resistance.
  • ERCC1 manipulation directly altered oxaliplatin sensitivity, validating its role as a mediator.

Conclusions:

  • KRAS mutation status serves as a predictive biomarker for oxaliplatin sensitivity in CRC.
  • The mechanism involves KRAS-mediated regulation of ERCC1 expression.
  • Findings suggest a novel therapeutic strategy targeting ERCC1 for improved CRC treatment outcomes.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...